Advanced search
Publication Cover
Expert Opinion on Medical Diagnostics Volume 1, 2007 - Issue 1
Journal homepage
31
Views
0
CrossRef citations to date
0
Altmetric
Review

Pharmacogenetics: where are we with respect to personalized medicine?

Joel A Lefferts Dartmouth Medical School, Department of Pathology, Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, One Medical Center Drive, Lebanon, NH 03756, USA +1 603 650 5498; +1 603 650 4845; [email protected]
, PhD (Post-Doctoral Fellow) ,
Claudine L Bartels Dartmouth Medical School, Department of Pathology, Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, One Medical Center Drive, Lebanon, NH 03756, USA +1 603 650 5498; +1 603 650 4845; [email protected]
, PhD (Post-Doctoral Fellow) &
Gregory J Tsongalis Dartmouth Medical School, Department of Pathology, Dartmouth Hitchcock Medical Center, Norris Cotton Cancer Center, One Medical Center Drive, Lebanon, NH 03756, USA +1 603 650 5498; +1 603 650 4845; [email protected]
, PhD (Director of Molecular Pathology)
Pages 117-128 | Published online: 12 Sep 2007

Bibliography

  • LONG RM: Planning for a national effort to enable and accelerate discoveries in pharmacogenetics: the NIH Pharmacogenetics Research Network. Clin. Pharmacol. Ther. (2007) 81:450-454.
  • EVANS WE, MCLEOD HL: Pharmacogenomics – drug disposition, drug targets, and side effects. N. Engl. J. Med. (2003) 348:538-549.
  • KIRCHHEINER J, FUHR U, BROCKMOLLER J: Pharmacogenetics-based therapeutic recommendations – ready for clinical practice? Nat. Rev. (2005) 4:639-647.
  • WEINSHILBOUM R, WAND L: Pharmacogenomics: bench to bedside. Nat. Rev. Drug Discov. (2004) 3:739-748.
  • DELEON J, ARMSTRONG SC, COZZA KL: Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics (2006) 47:75-85.
  • BAILEY DS, BONDAR A, FURNESS LM: Pharmacogenomics – it's not just pharmacogenetics. Curr. Opin. Biotechnol. (1998) 9:595-601.
  • TSONGALIS GJ, COLEMAN WB: Clinical genotyping: the need for interrogation of single nucleotide polymorphisms and mutations in the clinical laboratory. Clin. Chim. Acta (2006) 363:127-137.
  • NEBERT DW, INGELMAN-SUNDBERG M, DALY AK: Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug metabolizing genes, their functional importance and nomenclature issues. Drug Metab. Rev. (1999) 31:467-487.
  • LAZAROU J, POMERANZ BH, COREY PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA (1998) 279:1200-1205.
  • SHASTRY BS: Pharmacogenetics and the concept of individualized medicine. Pharmacogenom. J. (2006) 6:16-21.
  • VOGEL F: Moderne probleme der Humangenetik. Ergeb Inn. Med. Kinderheilkd (1959) 12:52-125.
  • NEBERT D: Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin. Genet. (1999) 56:247-258.
  • WEBER WW: Populations and genetic polymorphisms. Mol. Diagn. (1999) 4:299-307.
  • MAGER J, GLAASER G, RAZIN A, IZAK G, BIEN S, NOAM M: Metabolic effects of pyrimidines derived from fava bean glycosides on human erythrocytes deficient in glucose-6-phosphate dehydrogenase. Biochem. Biophys. Res. Commun. (1965) 20:235-240.
  • PODDA M, FIORELLI G, IDEO G, SPANO G, DIOGUARDI N: In-vitro-effect of a fava bean extract and of its fractions on reduced glutathione in glucose-6-phosphate dehydrogenase deficient red cells. Folia Haematol. Int. Mag. Klin. Morphol. Blutforsch. (1969) 91:51-55.
  • SNYDER LH: Studies in human inheritance. The inheritance of taste deficiency in man. Ohio J. Sci. (1932) 32:436-468.
  • EVANS DAP: N-acetyltransferase. Pharmaco. Ther. (1989) 42:157-234.
  • CARSON PE, FLANAGAN CL, ICKES CE, ALVING AS: Enzymatic deficiency in primaquine-sensitive erythrocytes. Science (1956) 124:484-485.
  • HAMMER W, SJOQVIST F. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci. (1967) 6:1895-903.
  • KALOW W: Familial incidence of low pseudocholinesterase level. Lancet (1956) 211:576-577.
  • WEINSHILBOUM R: Inheritance and drug response. N. Engl. J. Med. (2003) 348:529-537.
  • HUGHES HB, BIEHL JP, JONES AP, SCHMIDT LH: Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am. Rev. Tuberc. (1954) 70:266-273.
  • EVANS WE, RELLING MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 286:487-491.
  • GARDINER SJ, BEGG EJ: Pharmacogenetics, drug metabolizing enzymes and clinical practice. Pharmacol. Rev. (2006) 58:521-581.
  • INGELMAN-SUNDBERG M: Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenom. J. (2005) 5:6-13.
  • INGELMAN-SUNDBERG M: Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol. Sci. (2004) 25:193-200.
  • HEIM MH, MEYER UA: Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics (1992) 14:49-58.
  • LEDESMA MC, AGUNDEZ JA: Identification of subtypes of CYP2D gene rearrangements among carriers of CYP2D6 gene deletion and duplication. Clin. Chem. (2005) 51:939-943.
  • ANDERSSON T, FLOCKHART DA, GOLDSTEIN DB et al.: Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin. Pharmacol. Ther. (2005) 78:559-581.
  • LEE HK, LEWIS LD, TSONGALIS GJ et al.: Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism. Clin. Chim. Acta (2006) 367:196-200.
  • LOCKHART AC, TIRONA RG, KIM RB: Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol. Cancer Ther. (2003) 2:685-698.
  • MARZOLINI C, TIRONA RG, KIM RB: Pharmacogenomics of the OATP and OAT families. Pharmacogenomics (2004) 5:273-282.
  • URQUHART BL, TIRONA RG, KIM RB: Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J. Clin. Pharmacol. (2007) 47:566-578.
  • BORST P, SCHINKEL AH, SMIT JJ et al.: Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol. Ther. (1993) 60:289-299.
  • KUSUHARA H, SUZUKI H, SUGIYAMA Y: The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. J. Pharm. Sci. (1998) 87:1025-1040.
  • TANIGAWARA Y: Role of P-glycoprotein in drug disposition. Ther. Drug Monit. (2000) 22:137-140.
  • AMBUDKAR SV, DEY S, HRYCYNA CA: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Ann. Rev. Pharmacol. Toxicol. (1999) 39:361-398.
  • HIGGINS CF, CALLAGHAN R, LINTON KJ et al.: Structure of the multidrug resistance P-glycoprotein. Semin. Cancer Biol. (1997) 8:135-142.
  • ROSENBERG MF, CALLAGHAN R, FORD RC, HIGGINS CF: Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. J. Biol. Chem. (1997) 272:10685-10694.
  • SAKAEDA T, NAKAMURA T, OKUMURA K: MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol. Pharm. Bull. (2002) 25:1391-1400.
  • HOFFMEYER S, BURK O, VON RICHTER O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA (2000) 97:3473-3478.
  • JAMROZIAK K, ROBAK T: Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies. Hematology (2004) 9:91-105.
  • VAN DER KOLK DM, DE VRIES EG, NOORDHOEK L et al.: Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia (2001) 15:1544-1553.
  • SCHAICH M, SOUCEK S, THIEDE C et al.: MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br. J. Haematol. (2005) 128:324-332.
  • JAMROZIAK K, BALCERCZAK E, CEBULA B et al.: No influence of 3435C > T ABCB1 (MDR1) gene polymorphism on risk of adult acute myeloid leukemia and P-glycoprotein expression in blast cells. Ther. Drug Monit. (2006) 28:707-711.
  • VAN DER HOLT B, VAN DEN HEUVEL-EIBRINK MM et al.: ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. Clin. Pharmacol. Ther. (2006) 80:427-439.
  • KIMCHI-SARFATY C, OH JM, KIM IW et al.: A ‘silent’ polymorphism in the MDR1 gene changes substrate specificity. Science (2007) 315:525-528.
  • SAMANI NJ, O'TOOLE L, CHANNER K, WOODS KL: A meta analysis of the association of the deletion allele of the angiotensin converting enzyme gene with myocardial infarction. Circulation (1996) 94:708-712.
  • GREEN SA, COLE G, JACINTO M, INNIS M, LIGGETT SB: A polymorphism of the human β2-adrenergic receptor within the fourth membrane alters ligand binding and functional properties of the receptor. J. Biol. Chem. (1993) 268:23116-23121.
  • SCHAAK S, MIALET-PEREZ J, FLORDELLIS C, PARIS H: Genetic variation of human adrenergic receptors: from molecular and functional properties to clinical and pharmacogenetic implications. Curr. Top. Med. Chem. (2007) 7:217-231.
  • Bhatnagar P, GULERIA R, KUKRETI R: Pharmacogenomics of β2-agonist: key focus on signaling pathways. Pharmacogenomics (2006) 7:919-933.
  • SHANKAR DB, LI J, TAPANG P, MCCALL JO et al.: ABT-869, a multitargeted receptor kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood (2007) 109:3400-3408.
  • GOETZ MP, RAE JM, SUMAN VJ et al.: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. (2005) 23:9312-9318.
  • GROUP EBCTC: Tamoxifen for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet (1998) 351:1451-1467.
  • POON GK, CHUI YC, MCCAGUE R et al.: Analysis of Phase I and Phase II metabolites of tamoxifen in breast cancer patients. Drug Metab. Dispos. (1993) 21:1119-1124.
  • KLEIN TE, CHANG JT, CHO MK et al.: Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenom. J. (2001) 1:167-170.
  • JIN Y, DESTA Z, STEARNS V et al.: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. NCI (2005) 97:30-39.
  • SACHSE C, BROCKMÖLLER J, BAUER S, ROOTS I: Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. (1997) 60(2):284-295.
  • LENNARD L, REES CA, LILLEYMAN JS, MADDOCKS JL: Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br. J. Clin. Pharmacol. (2004) 58:S867-S871.
  • SALAVAGGIONE OE, WANG L, WIEPERT M, YEE VC, WEINSHILBOUM RM: Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet. Genom. (2005) 15:801-815.
  • WEINSHILBOUM RM, SLADEK SL: Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. (1980) 32:651-662.
  • YATES CR, KRYNETSKI EY, LOENNECHEN T et al.: Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. (1997) 126:608-614.
  • LENNARD L, LILLEYMAN JS, VAN LOON J, WEINSHILBOUM RM: Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet (1990) 336:225-229.
  • WASSERMAN E, MYARA A, LOKIEC F et al.: Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann. Oncol. (1997) 8:1049-1051.
  • HUMERICKHOUSE R, LOHRBACH K, LI L, BOSRON WF, DOLAN ME: Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res. (2000) 60:1189-1192.
  • HARTMANN JT, LIPP HP: Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II – mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf. (2006) 29:209-230.
  • MAITLAND ML, VASISHT K, RATAIN MJ: TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol. Sci. (2006) 27:432-437.
  • LINDER MW, PROUGH RA, VALDES R Jr: Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin. Chem. (1997) 43:254-266.
  • SCHUR BC, BJERKE J, NUWAYHID N, WONG SH: Genotyping of cytochrome P450 2D6*3 and *4 mutations using conventional PCR. Clin. Chim. Acta (2001) 308:25-31.
  • LUCAS T, LOSERT D, ALLEN M et al.: Combination of allele-specific real time PCR for differentiation of β2-adrenergic receptor coding single nucelotide polymorphisms. Clin. Chem. (2004) 50:769-772.
  • LEE HK, LEWIS LD, TSONGALIS GJ et al.: Validation of a CYP2D6 genotyping panel on the nanochip molecular biology workstation. Clin. Chem. (2007) 53:823-828.
  • FERRARI M, CREMONESI L, BONINI P et al.: Single-nucleotide polymorphism and mutation identification by the nanogen microelectronic chip technology. Methods Mol. Med. (2005) 114:93-106.
  • ERALI M, SCHMIDT B, LYON E, WITTWER C: Evaluation of electronic microarrays for genotyping factor V, factor II, and MTHFR. Clin. Chem. (2003) 49:732-739.
  • JAIN KK: Applications of AmpliChip CYP450. Mol. Diagn. (2005) 9:119-127.
  • VAIRAVAN R: AutoGenomics, Inc. Pharmacogenomics (2004) 5:585-588.
  • BORTOLIN S, BLACK M, MODI H et al.: Analytical validation of the tag-it high-throughput microsphere-based universal array genotyping platform: application to the multiplex detection of a panel of thrombophilia-associated single-nucleotide polymorphisms. Clin. Chem (2004) 50:2028-2036.

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.